NasdaqGM:TARA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. More Details


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has Protara Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TARA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: TARA's weekly volatility (10%) has been stable over the past year.


Market Performance


7 Day Return

6.3%

TARA

2.8%

US Biotechs

1.5%

US Market


1 Year Return

n/a

TARA

27.3%

US Biotechs

22.3%

US Market

Return vs Industry: Insufficient data to determine how TARA performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how TARA performed against the US Market.


Shareholder returns

TARAIndustryMarket
7 Day6.3%2.8%1.5%
30 Day33.4%7.8%8.8%
90 Day25.1%17.5%10.8%
1 Yearn/a29.5%27.3%25.1%22.3%
3 Yearn/a26.5%20.1%49.5%39.6%
5 Yearn/a21.0%12.7%105.8%83.3%

Long-Term Price Volatility Vs. Market

How volatile is Protara Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Protara Therapeutics undervalued compared to its fair value and its price relative to the market?

1192.71x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TARA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TARA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TARA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: TARA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TARA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TARA is overvalued based on its PB Ratio (1192.7x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Protara Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-23.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TARA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TARA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TARA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if TARA's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if TARA's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TARA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Protara Therapeutics performed over the past 5 years?

-93.0%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: TARA is currently unprofitable.

Growing Profit Margin: TARA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if TARA's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare TARA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TARA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.8%).


Return on Equity

High ROE: TARA has a negative Return on Equity (-2357.86%), as it is currently unprofitable.


Next Steps

Financial Health

How is Protara Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: TARA's short term assets ($1.8M) do not cover its short term liabilities ($1.9M).

Long Term Liabilities: TARA has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: TARA is debt free.

Reducing Debt: TARA had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if TARA has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if TARA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Protara Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TARA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TARA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TARA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TARA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TARA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average board tenure


CEO

Jesse Shefferman (48 yo)

3.08yrs

Tenure

US$379,076

Compensation

Mr. Jesse Shefferman is the Co-Founder of Proteon Therapeutics Inc. (Formerly known as Protara Therapeutics, Inc. (formerly known as ArTara Therapeutics, Inc.).) and also serves as its President & CEO sinc...


CEO Compensation Analysis

Compensation vs Market: Jesse's total compensation ($USD379.08K) is below average for companies of similar size in the US market ($USD1.10M).

Compensation vs Earnings: Jesse's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Jesse Shefferman
Co-Founder3.08yrsUS$379.08k7.05%
$ 19.5m
Luke Beshar
Independent Chairman of the Boardno dataUS$111.63k0.50%
$ 1.4m
Richard Levy
Independent Director1yrUS$3.75kno data
Gregory Sargen
Independent Director1.08yrsUS$6.38kno data
Michael Solomon
Independent Directorno dataUS$82.88k0.079%
$ 217.9k
Roger Garceau
Independent Director1.92yrsUS$84.38k0.098%
$ 271.4k
Barry Flannelly
Director0.42yrno datano data

1.0yrs

Average Tenure

61yo

Average Age

Experienced Board: TARA's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TARA insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: TARA only recently listed within the past 12 months.


Top Shareholders

Company Information

Protara Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Protara Therapeutics, Inc.
  • Ticker: TARA
  • Exchange: NasdaqGM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$276.596m
  • Shares outstanding: 11.21m
  • Website: https://www.protaratx.com

Number of Employees


Location

  • Protara Therapeutics, Inc.
  • 1 Little West 12th Street
  • New York
  • New York
  • 10014
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TARANasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJan 2020
1KPADB (Deutsche Boerse AG)YesCommon StockDEEURJan 2020

Biography

Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company’s lead program is TARA-002, ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/04 23:20
End of Day Share Price2020/12/04 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.